Advisors Asset Management Inc. Increases Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Advisors Asset Management Inc. boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.1% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 4,767 shares of the biopharmaceutical company’s stock after buying an additional 189 shares during the quarter. Advisors Asset Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $1,311,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at $26,000. Huntington National Bank grew its holdings in Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the last quarter. Hollencrest Capital Management bought a new position in Alnylam Pharmaceuticals during the 3rd quarter valued at about $29,000. Washington Trust Advisors Inc. purchased a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth about $42,000. Finally, Friedenthal Financial bought a new stake in Alnylam Pharmaceuticals in the third quarter worth about $51,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $250.98 on Tuesday. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The company has a market capitalization of $32.37 billion, a PE ratio of -95.79 and a beta of 0.39. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The company has a 50-day simple moving average of $273.13 and a two-hundred day simple moving average of $238.67.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. During the same period last year, the firm earned $1.15 earnings per share. The firm’s revenue was down 33.3% compared to the same quarter last year. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on ALNY shares. Canaccord Genuity Group increased their price target on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Cantor Fitzgerald reiterated a “neutral” rating and set a $220.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. JPMorgan Chase & Co. upped their price target on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a report on Monday, August 26th. The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $198.00 to $370.00 in a report on Friday, August 16th. Finally, Chardan Capital restated a “buy” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $298.09.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.